Roivant Sciences Ltd. (ROIV) Stock Competitors & Peer Comparison
See (ROIV) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ROIV | $29.09 | -3.00% | 20.9B | -53.87 | -$0.54 | N/A |
| NVO | $44.06 | -3.33% | 195.8B | 10.34 | $4.26 | +3.94% |
| VRTX | $438.40 | -2.04% | 111.3B | 25.99 | $16.87 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $600.71 | -2.29% | 61.9B | 14.67 | $40.94 | +0.59% |
| ARGX | $836.09 | +0.01% | 51.7B | 37.08 | $22.55 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $295.63 | -2.10% | 39.5B | 74.09 | $3.99 | N/A |
| RVMD | $163.68 | +3.94% | 34.8B | -23.02 | -$7.11 | N/A |
| RPRX | $55.18 | -1.04% | 23.7B | 29.04 | $1.90 | +1.66% |
Stock Comparison
ROIV vs NVO Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, NVO has a market cap of 195.8B. Regarding current trading prices, ROIV is priced at $29.09, while NVO trades at $44.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas NVO's P/E ratio is 10.34. In terms of profitability, ROIV's ROE is -0.07%, compared to NVO's ROE of +0.66%. Regarding short-term risk, ROIV is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check NVO's competition here
ROIV vs VRTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, VRTX has a market cap of 111.3B. Regarding current trading prices, ROIV is priced at $29.09, while VRTX trades at $438.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas VRTX's P/E ratio is 25.99. In terms of profitability, ROIV's ROE is -0.07%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ROIV is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check VRTX's competition here
ROIV vs VRNA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ROIV is priced at $29.09, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ROIV's ROE is -0.07%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ROIV is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check VRNA's competition here
ROIV vs REGN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, REGN has a market cap of 61.9B. Regarding current trading prices, ROIV is priced at $29.09, while REGN trades at $600.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas REGN's P/E ratio is 14.67. In terms of profitability, ROIV's ROE is -0.07%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ROIV is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check REGN's competition here
ROIV vs ARGX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ARGX has a market cap of 51.7B. Regarding current trading prices, ROIV is priced at $29.09, while ARGX trades at $836.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ARGX's P/E ratio is 37.08. In terms of profitability, ROIV's ROE is -0.07%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, ROIV is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ARGX's competition here
ROIV vs SGEN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ROIV is priced at $29.09, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ROIV's ROE is -0.07%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ROIV is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check SGEN's competition here
ROIV vs ALNY Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ALNY has a market cap of 39.5B. Regarding current trading prices, ROIV is priced at $29.09, while ALNY trades at $295.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ALNY's P/E ratio is 74.09. In terms of profitability, ROIV's ROE is -0.07%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ROIV is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check ALNY's competition here
ROIV vs RVMD Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, RVMD has a market cap of 34.8B. Regarding current trading prices, ROIV is priced at $29.09, while RVMD trades at $163.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas RVMD's P/E ratio is -23.02. In terms of profitability, ROIV's ROE is -0.07%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ROIV is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check RVMD's competition here
ROIV vs RPRX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, RPRX has a market cap of 23.7B. Regarding current trading prices, ROIV is priced at $29.09, while RPRX trades at $55.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas RPRX's P/E ratio is 29.04. In terms of profitability, ROIV's ROE is -0.07%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, ROIV is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check RPRX's competition here
ROIV vs BNTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, BNTX has a market cap of 23.2B. Regarding current trading prices, ROIV is priced at $29.09, while BNTX trades at $91.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas BNTX's P/E ratio is -15.57. In terms of profitability, ROIV's ROE is -0.07%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ROIV is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check BNTX's competition here
ROIV vs UTHR Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, UTHR has a market cap of 23.1B. Regarding current trading prices, ROIV is priced at $29.09, while UTHR trades at $544.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas UTHR's P/E ratio is 20.13. In terms of profitability, ROIV's ROE is -0.07%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ROIV is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check UTHR's competition here
ROIV vs INSM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, INSM has a market cap of 23B. Regarding current trading prices, ROIV is priced at $29.09, while INSM trades at $106.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas INSM's P/E ratio is -18.41. In terms of profitability, ROIV's ROE is -0.07%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ROIV is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check INSM's competition here
ROIV vs BGNE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ROIV is priced at $29.09, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ROIV's ROE is -0.07%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ROIV is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check BGNE's competition here
ROIV vs INCY Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, INCY has a market cap of 19.1B. Regarding current trading prices, ROIV is priced at $29.09, while INCY trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas INCY's P/E ratio is 13.50. In terms of profitability, ROIV's ROE is -0.07%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ROIV is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check INCY's competition here
ROIV vs DNA-WT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ROIV is priced at $29.09, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ROIV's ROE is -0.07%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ROIV is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check DNA-WT's competition here
ROIV vs MRNA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, MRNA has a market cap of 18.3B. Regarding current trading prices, ROIV is priced at $29.09, while MRNA trades at $46.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas MRNA's P/E ratio is -5.66. In terms of profitability, ROIV's ROE is -0.07%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ROIV is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check MRNA's competition here
ROIV vs NBIX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, NBIX has a market cap of 16.2B. Regarding current trading prices, ROIV is priced at $29.09, while NBIX trades at $161.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas NBIX's P/E ratio is 24.73. In terms of profitability, ROIV's ROE is -0.07%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ROIV is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check NBIX's competition here
ROIV vs GMAB Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, GMAB has a market cap of 15.6B. Regarding current trading prices, ROIV is priced at $29.09, while GMAB trades at $25.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas GMAB's P/E ratio is 19.43. In terms of profitability, ROIV's ROE is -0.07%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, ROIV is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check GMAB's competition here
ROIV vs JAZZ Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, JAZZ has a market cap of 14.6B. Regarding current trading prices, ROIV is priced at $29.09, while JAZZ trades at $232.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas JAZZ's P/E ratio is 1938.67. In terms of profitability, ROIV's ROE is -0.07%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ROIV is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check JAZZ's competition here
ROIV vs ASND Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ASND has a market cap of 13.5B. Regarding current trading prices, ROIV is priced at $29.09, while ASND trades at $218.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ASND's P/E ratio is 24.87. In terms of profitability, ROIV's ROE is -0.07%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ROIV is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check ASND's competition here
ROIV vs BBIO Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, BBIO has a market cap of 12.8B. Regarding current trading prices, ROIV is priced at $29.09, while BBIO trades at $65.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas BBIO's P/E ratio is -17.48. In terms of profitability, ROIV's ROE is -0.07%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ROIV is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check BBIO's competition here
ROIV vs EXEL Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, EXEL has a market cap of 12.6B. Regarding current trading prices, ROIV is priced at $29.09, while EXEL trades at $50.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas EXEL's P/E ratio is 16.65. In terms of profitability, ROIV's ROE is -0.07%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ROIV is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check EXEL's competition here
ROIV vs KRTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ROIV is priced at $29.09, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ROIV's ROE is -0.07%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ROIV is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check KRTX's competition here
ROIV vs IONS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, ROIV is priced at $29.09, while IONS trades at $75.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas IONS's P/E ratio is -37.50. In terms of profitability, ROIV's ROE is -0.07%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ROIV is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check IONS's competition here
ROIV vs SMMT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, SMMT has a market cap of 12.2B. Regarding current trading prices, ROIV is priced at $29.09, while SMMT trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas SMMT's P/E ratio is -9.88. In terms of profitability, ROIV's ROE is -0.07%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ROIV is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check SMMT's competition here
ROIV vs AXSM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, AXSM has a market cap of 11.8B. Regarding current trading prices, ROIV is priced at $29.09, while AXSM trades at $230.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas AXSM's P/E ratio is -62.06. In terms of profitability, ROIV's ROE is -0.07%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ROIV is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check AXSM's competition here
ROIV vs RNAM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ROIV is priced at $29.09, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ROIV's ROE is -0.07%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ROIV is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check RNAM's competition here
ROIV vs MDGL Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, MDGL has a market cap of 11.1B. Regarding current trading prices, ROIV is priced at $29.09, while MDGL trades at $481.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas MDGL's P/E ratio is -35.70. In terms of profitability, ROIV's ROE is -0.07%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ROIV is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check MDGL's competition here
ROIV vs BMRN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, ROIV is priced at $29.09, while BMRN trades at $55.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas BMRN's P/E ratio is 39.59. In terms of profitability, ROIV's ROE is -0.07%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ROIV is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check BMRN's competition here
ROIV vs ARWR Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ARWR has a market cap of 10.6B. Regarding current trading prices, ROIV is priced at $29.09, while ARWR trades at $75.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ARWR's P/E ratio is -33.13. In terms of profitability, ROIV's ROE is -0.07%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ROIV is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check ARWR's competition here
ROIV vs RXDX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ROIV is priced at $29.09, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ROIV's ROE is -0.07%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ROIV is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check RXDX's competition here
ROIV vs CYTK Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, ROIV is priced at $29.09, while CYTK trades at $73.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CYTK's P/E ratio is -10.76. In terms of profitability, ROIV's ROE is -0.07%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ROIV is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check CYTK's competition here
ROIV vs KRYS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, KRYS has a market cap of 8.8B. Regarding current trading prices, ROIV is priced at $29.09, while KRYS trades at $298.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas KRYS's P/E ratio is 39.96. In terms of profitability, ROIV's ROE is -0.07%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ROIV is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check KRYS's competition here
ROIV vs IMGN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ROIV is priced at $29.09, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ROIV's ROE is -0.07%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ROIV is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check IMGN's competition here
ROIV vs ABVX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, ROIV is priced at $29.09, while ABVX trades at $129.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ABVX's P/E ratio is -24.20. In terms of profitability, ROIV's ROE is -0.07%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ROIV is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check ABVX's competition here
ROIV vs BPMC Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ROIV is priced at $29.09, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ROIV's ROE is -0.07%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ROIV is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check BPMC's competition here
ROIV vs CERE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ROIV is priced at $29.09, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CERE's P/E ratio is -16.47. In terms of profitability, ROIV's ROE is -0.07%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ROIV is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CERE's competition here
ROIV vs HALO Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, ROIV is priced at $29.09, while HALO trades at $68.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas HALO's P/E ratio is 23.91. In terms of profitability, ROIV's ROE is -0.07%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ROIV is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check HALO's competition here
ROIV vs TECH Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, TECH has a market cap of 8B. Regarding current trading prices, ROIV is priced at $29.09, while TECH trades at $50.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas TECH's P/E ratio is 72.56. In terms of profitability, ROIV's ROE is -0.07%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ROIV is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check TECH's competition here
ROIV vs IBRX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, ROIV is priced at $29.09, while IBRX trades at $7.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas IBRX's P/E ratio is -8.52. In terms of profitability, ROIV's ROE is -0.07%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ROIV is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check IBRX's competition here
ROIV vs CORT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, ROIV is priced at $29.09, while CORT trades at $70.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CORT's P/E ratio is 201.26. In terms of profitability, ROIV's ROE is -0.07%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ROIV is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check CORT's competition here
ROIV vs MTSR Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ROIV is priced at $29.09, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ROIV's ROE is -0.07%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ROIV is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check MTSR's competition here
ROIV vs PRAX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, ROIV is priced at $29.09, while PRAX trades at $335.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas PRAX's P/E ratio is -25.01. In terms of profitability, ROIV's ROE is -0.07%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ROIV is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check PRAX's competition here
ROIV vs PCVX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, PCVX has a market cap of 7.1B. Regarding current trading prices, ROIV is priced at $29.09, while PCVX trades at $48.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas PCVX's P/E ratio is -7.10. In terms of profitability, ROIV's ROE is -0.07%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ROIV is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check PCVX's competition here
ROIV vs ALKS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ALKS has a market cap of 7B. Regarding current trading prices, ROIV is priced at $29.09, while ALKS trades at $42.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ALKS's P/E ratio is 46.97. In terms of profitability, ROIV's ROE is -0.07%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ROIV is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check ALKS's competition here
ROIV vs NUVL Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, NUVL has a market cap of 6.8B. Regarding current trading prices, ROIV is priced at $29.09, while NUVL trades at $93.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas NUVL's P/E ratio is -15.35. In terms of profitability, ROIV's ROE is -0.07%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ROIV is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check NUVL's competition here
ROIV vs MRUS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ROIV is priced at $29.09, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ROIV's ROE is -0.07%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ROIV is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check MRUS's competition here
ROIV vs IMVT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, IMVT has a market cap of 6.7B. Regarding current trading prices, ROIV is priced at $29.09, while IMVT trades at $32.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas IMVT's P/E ratio is -11.86. In terms of profitability, ROIV's ROE is -0.07%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ROIV is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check IMVT's competition here
ROIV vs ACLX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ROIV is priced at $29.09, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ROIV's ROE is -0.07%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ROIV is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ACLX's competition here
ROIV vs RETA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ROIV is priced at $29.09, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas RETA's P/E ratio is -66.29. In terms of profitability, ROIV's ROE is -0.07%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ROIV is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check RETA's competition here
ROIV vs KYMR Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, ROIV is priced at $29.09, while KYMR trades at $78.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas KYMR's P/E ratio is -21.92. In terms of profitability, ROIV's ROE is -0.07%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ROIV is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check KYMR's competition here
ROIV vs CNTA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, ROIV is priced at $29.09, while CNTA trades at $39.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CNTA's P/E ratio is -22.39. In terms of profitability, ROIV's ROE is -0.07%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ROIV is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CNTA's competition here
ROIV vs PTCT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, ROIV is priced at $29.09, while PTCT trades at $73.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas PTCT's P/E ratio is -29.06. In terms of profitability, ROIV's ROE is -0.07%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ROIV is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check PTCT's competition here
ROIV vs PTGX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, PTGX has a market cap of 6.1B. Regarding current trading prices, ROIV is priced at $29.09, while PTGX trades at $94.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas PTGX's P/E ratio is -52.35. In terms of profitability, ROIV's ROE is -0.07%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ROIV is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check PTGX's competition here
ROIV vs RYTM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, ROIV is priced at $29.09, while RYTM trades at $87.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas RYTM's P/E ratio is -28.07. In terms of profitability, ROIV's ROE is -0.07%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ROIV is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check RYTM's competition here
ROIV vs CELC Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CELC has a market cap of 6B. Regarding current trading prices, ROIV is priced at $29.09, while CELC trades at $122.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CELC's P/E ratio is -31.53. In terms of profitability, ROIV's ROE is -0.07%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ROIV is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check CELC's competition here
ROIV vs COGT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, ROIV is priced at $29.09, while COGT trades at $34.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas COGT's P/E ratio is -16.04. In terms of profitability, ROIV's ROE is -0.07%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ROIV is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check COGT's competition here
ROIV vs BLTE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, ROIV is priced at $29.09, while BLTE trades at $147.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas BLTE's P/E ratio is -57.65. In terms of profitability, ROIV's ROE is -0.07%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, ROIV is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check BLTE's competition here
ROIV vs TGTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, TGTX has a market cap of 5.7B. Regarding current trading prices, ROIV is priced at $29.09, while TGTX trades at $37.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas TGTX's P/E ratio is 13.08. In terms of profitability, ROIV's ROE is -0.07%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ROIV is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check TGTX's competition here
ROIV vs SRRK Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ROIV is priced at $29.09, while SRRK trades at $47.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas SRRK's P/E ratio is -13.74. In terms of profitability, ROIV's ROE is -0.07%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ROIV is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check SRRK's competition here
ROIV vs CDTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ROIV is priced at $29.09, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ROIV's ROE is -0.07%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ROIV is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CDTX's competition here
ROIV vs ABCM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ROIV is priced at $29.09, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ROIV's ROE is -0.07%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ROIV is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ABCM's competition here
ROIV vs ISEE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ROIV is priced at $29.09, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ROIV's ROE is -0.07%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ROIV is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ISEE's competition here
ROIV vs APLS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ROIV is priced at $29.09, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas APLS's P/E ratio is 38.35. In terms of profitability, ROIV's ROE is -0.07%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ROIV is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check APLS's competition here
ROIV vs CRSP Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, ROIV is priced at $29.09, while CRSP trades at $54.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CRSP's P/E ratio is -8.78. In terms of profitability, ROIV's ROE is -0.07%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ROIV is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check CRSP's competition here
ROIV vs CGON Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CGON has a market cap of 5.2B. Regarding current trading prices, ROIV is priced at $29.09, while CGON trades at $59.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CGON's P/E ratio is -25.31. In terms of profitability, ROIV's ROE is -0.07%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ROIV is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check CGON's competition here
ROIV vs LQDA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, LQDA has a market cap of 5.2B. Regarding current trading prices, ROIV is priced at $29.09, while LQDA trades at $58.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas LQDA's P/E ratio is 345.56. In terms of profitability, ROIV's ROE is -0.07%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ROIV is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check LQDA's competition here
ROIV vs FBIOX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, ROIV is priced at $29.09, while FBIOX trades at $25.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ROIV's ROE is -0.07%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ROIV is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check FBIOX's competition here
ROIV vs APGE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, APGE has a market cap of 4.9B. Regarding current trading prices, ROIV is priced at $29.09, while APGE trades at $79.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas APGE's P/E ratio is -18.31. In terms of profitability, ROIV's ROE is -0.07%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ROIV is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check APGE's competition here
ROIV vs MIRM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, ROIV is priced at $29.09, while MIRM trades at $96.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas MIRM's P/E ratio is -7.08. In terms of profitability, ROIV's ROE is -0.07%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ROIV is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check MIRM's competition here
ROIV vs TERN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ROIV is priced at $29.09, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas TERN's P/E ratio is -51.41. In terms of profitability, ROIV's ROE is -0.07%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ROIV is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check TERN's competition here
ROIV vs LEGN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, LEGN has a market cap of 4.7B. Regarding current trading prices, ROIV is priced at $29.09, while LEGN trades at $25.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas LEGN's P/E ratio is -18.49. In terms of profitability, ROIV's ROE is -0.07%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ROIV is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check LEGN's competition here
ROIV vs CAI Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, ROIV is priced at $29.09, while CAI trades at $16.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CAI's P/E ratio is -5.96. In terms of profitability, ROIV's ROE is -0.07%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ROIV is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check CAI's competition here
ROIV vs LGND Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, ROIV is priced at $29.09, while LGND trades at $229.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas LGND's P/E ratio is 29.92. In terms of profitability, ROIV's ROE is -0.07%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ROIV is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check LGND's competition here
ROIV vs FOLD Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ROIV is priced at $29.09, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ROIV's ROE is -0.07%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ROIV is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check FOLD's competition here
ROIV vs AKRO Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ROIV is priced at $29.09, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ROIV's ROE is -0.07%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ROIV is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check AKRO's competition here
ROIV vs ALPN Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ROIV is priced at $29.09, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ROIV's ROE is -0.07%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ROIV is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check ALPN's competition here
ROIV vs EWTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, ROIV is priced at $29.09, while EWTX trades at $40.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas EWTX's P/E ratio is -24.25. In terms of profitability, ROIV's ROE is -0.07%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ROIV is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check EWTX's competition here
ROIV vs ERAS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ERAS has a market cap of 4.3B. Regarding current trading prices, ROIV is priced at $29.09, while ERAS trades at $13.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ERAS's P/E ratio is -14.86. In terms of profitability, ROIV's ROE is -0.07%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ROIV is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check ERAS's competition here
ROIV vs SYRE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, SYRE has a market cap of 4.3B. Regarding current trading prices, ROIV is priced at $29.09, while SYRE trades at $70.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas SYRE's P/E ratio is -33.27. In terms of profitability, ROIV's ROE is -0.07%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ROIV is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check SYRE's competition here
ROIV vs MANE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, ROIV is priced at $29.09, while MANE trades at $101.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas MANE's P/E ratio is -38.50. In terms of profitability, ROIV's ROE is -0.07%, compared to MANE's ROE of -0.95%. Regarding short-term risk, ROIV is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check MANE's competition here
ROIV vs OPT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ROIV is priced at $29.09, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas OPT's P/E ratio is -1.52. In terms of profitability, ROIV's ROE is -0.07%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ROIV is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check OPT's competition here
ROIV vs XENE Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, XENE has a market cap of 4.2B. Regarding current trading prices, ROIV is priced at $29.09, while XENE trades at $53.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas XENE's P/E ratio is -11.36. In terms of profitability, ROIV's ROE is -0.07%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ROIV is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check XENE's competition here
ROIV vs TVTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, TVTX has a market cap of 4.2B. Regarding current trading prices, ROIV is priced at $29.09, while TVTX trades at $45.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas TVTX's P/E ratio is -90.08. In terms of profitability, ROIV's ROE is -0.07%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ROIV is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check TVTX's competition here
ROIV vs MRTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ROIV is priced at $29.09, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ROIV's ROE is -0.07%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ROIV is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check MRTX's competition here
ROIV vs VCYT Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, ROIV is priced at $29.09, while VCYT trades at $48.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas VCYT's P/E ratio is 44.61. In terms of profitability, ROIV's ROE is -0.07%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, ROIV is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check VCYT's competition here
ROIV vs CPRX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, ROIV is priced at $29.09, while CPRX trades at $31.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CPRX's P/E ratio is 18.08. In terms of profitability, ROIV's ROE is -0.07%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ROIV is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CPRX's competition here
ROIV vs RYZB Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ROIV is priced at $29.09, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ROIV's ROE is -0.07%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ROIV is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check RYZB's competition here
ROIV vs DNTH Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, DNTH has a market cap of 3.7B. Regarding current trading prices, ROIV is priced at $29.09, while DNTH trades at $89.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas DNTH's P/E ratio is -21.15. In terms of profitability, ROIV's ROE is -0.07%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ROIV is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check DNTH's competition here
ROIV vs CBAY Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ROIV is priced at $29.09, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ROIV's ROE is -0.07%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ROIV is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check CBAY's competition here
ROIV vs NAMS Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, ROIV is priced at $29.09, while NAMS trades at $31.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas NAMS's P/E ratio is -17.86. In terms of profitability, ROIV's ROE is -0.07%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ROIV is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check NAMS's competition here
ROIV vs ACAD Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, ROIV is priced at $29.09, while ACAD trades at $21.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas ACAD's P/E ratio is 9.74. In terms of profitability, ROIV's ROE is -0.07%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ROIV is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check ACAD's competition here
ROIV vs KNSA Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, ROIV is priced at $29.09, while KNSA trades at $48.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas KNSA's P/E ratio is 53.22. In terms of profitability, ROIV's ROE is -0.07%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, ROIV is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check KNSA's competition here
ROIV vs CRNX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, CRNX has a market cap of 3.6B. Regarding current trading prices, ROIV is priced at $29.09, while CRNX trades at $34.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas CRNX's P/E ratio is -6.72. In terms of profitability, ROIV's ROE is -0.07%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ROIV is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check CRNX's competition here
ROIV vs VKTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, ROIV is priced at $29.09, while VKTX trades at $31.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas VKTX's P/E ratio is -7.53. In terms of profitability, ROIV's ROE is -0.07%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ROIV is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check VKTX's competition here
ROIV vs SWTX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ROIV is priced at $29.09, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ROIV's ROE is -0.07%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ROIV is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ROIV.Check SWTX's competition here
ROIV vs DNLI Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, ROIV is priced at $29.09, while DNLI trades at $20.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas DNLI's P/E ratio is -7.09. In terms of profitability, ROIV's ROE is -0.07%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ROIV is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check DNLI's competition here
ROIV vs BEAM Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, BEAM has a market cap of 3.2B. Regarding current trading prices, ROIV is priced at $29.09, while BEAM trades at $31.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas BEAM's P/E ratio is -63.55. In terms of profitability, ROIV's ROE is -0.07%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, ROIV is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check BEAM's competition here
ROIV vs TLX Comparison June 2026
ROIV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ROIV stands at 20.9B. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, ROIV is priced at $29.09, while TLX trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ROIV currently has a P/E ratio of -53.87, whereas TLX's P/E ratio is -471.00. In terms of profitability, ROIV's ROE is -0.07%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ROIV is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for ROIV.Check TLX's competition here